A Mario Marcondes, MD PhD
About A Mario Marcondes, MD PhD
A Mario Marcondes, MD PhD, serves as the Executive Director of Clinical Development at Nektar Therapeutics, where he has worked since 2019. He has extensive experience in clinical research and development, particularly in hematology and oncology, and has held various roles in prominent research institutions and companies.
Current Role at Nektar Therapeutics
A Mario Marcondes serves as the Executive Director of Clinical Development at Nektar Therapeutics, a position he has held since 2019. In this role, he oversees clinical development strategies and initiatives, focusing on advancing innovative therapies. His leadership contributes to the company's mission in the biopharmaceutical sector, particularly in the fields of immuno-oncology.
Previous Experience at Fred Hutchinson Cancer Research Center
Prior to his current role, A Mario Marcondes worked at Fred Hutchinson Cancer Research Center as a Research Member from 2010 to 2012. During his tenure, he contributed to various research projects aimed at understanding cancer biology and treatment options. He also served as a Post Doctoral Fellow at the same institution from 2007 to 2010, further enhancing his expertise in clinical research.
Educational Background and Medical Training
A Mario Marcondes completed his Doctor of Medicine (MD) at Taubate Sao Paulo Medical School from 1994 to 2000. He furthered his medical education with a residency in Internal Medicine at Public Servant Hospital Sao Paulo from 2000 to 2002, followed by a residency in Hematology-Oncology from 2002 to 2004. He obtained a PhD in Pathology/Experimental Pathology from the University of Washington between 2006 and 2010.
Clinical Research and Development Expertise
A Mario Marcondes has extensive experience in managing Phase 1/2 clinical programs, which includes planning and executing investigator meetings and Data Monitoring Committee (DMC) meetings, as well as handling regulatory submissions. His expertise encompasses hematologic and oncologic paradigms, particularly in post Bone Marrow transplant settings, including graft-versus-host disease (GVHD), hematopoietic stem cell transplantation (HSCT), and CAR-T therapies.
Professional Affiliations and Skills
A Mario Marcondes is a member of several professional organizations, including the American Society of Clinical Oncology and the American Society of Hematology. He possesses strong scientific oral presentation and writing skills in English, Portuguese, and Spanish, along with basic knowledge of French and Italian, which supports his collaborative work in diverse research environments.